Another in vivo study indicated that TNF-α levels were reduced, as well as the clinical signs of MS, and the neuroimaging abnormalities on an MRI were prevented in marmoset models of EAE treated with rolipram [90] (Table 2). This evidence concerns the gene TNF and myeloid sarcoma.